Adding adjuvant chemotherapy to radiotherapy did not lead to a significant survival benefit over radiotherapy alone in women ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...

Finally, adjuvant chemotherapy was associated with improved survival in the high-risk group but not in the low-risk group (treatment-model interaction P = .01 and .006) for stage II/III gastric and ...

Chemotherapy plus local therapy improved overall survival and disease-free survival when compared to local therapy alone.

Clinical guidelines should establish clear timelines, and health care systems should prioritize timely treatment initiation and completion,” researchers concluded.

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...